ELCRX Mutual Fund

ELCRX Mutual Fund

NAV$41.37
See how much of ELCRX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Jul 31, 2026

Net Assets
$4M
Expense Ratio
1.29%
Dividend Yield (Current)
15.51%
Holdings
50
Inception Date
Aug 3, 2009
Fund Family
Eaton Vance
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+2.95%
1 Year+7.88%
3 Year+18.45%
5 Year+8.75%
10 Year+14.56%

Asset Allocation

Stocks: 99.79%
Bonds: 0.21%
See how much of ELCRX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
NVDANvidia Corp12.97%
AAPLApple, Inc7.68%
AVGOBroadcom Inc7.34%
MSFTMicrosoft Corp6.29%
GOOGLAlphabet Inc,class A5.72%
Top 10 Concentration: 56.74%Report Date: Jul 31, 2026
Download all 50 holdings for ELCRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
15.51%
Frequency
Annually
Latest Distribution
$3.36
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

ELCRX Mutual Fund Overview

ELCRX Mutual Fund (Eaton Vance Growth Fund Class R) is managed by Eaton Vance with $3.5M in net assets. ELCRX expense ratio is 1.29%, holding 50 positions across sectors including Information Technology, Communication Services, Consumer Discretionary. Inception date: 2009-08-03.

ELCRX performance shows a YTD return of 2.95%. The 1-year return is 7.88% and the 5-year return is 8.75%. ELCRX dividend yield stands at 15.51%, paid annually.

ELCRX top holdings include Nvidia Corp (13.0%), Apple, Inc (7.7%), Broadcom Inc (7.3%), Microsoft Corp (6.3%), Alphabet Inc,class A (5.7%). Go to all ELCRX holdings, ELCRX sectors, or ELCRX dividends.

ELCRX can be compared against other funds. Use ELCRX overlap to find shared positions, or ELCRX vs another fund for a side-by-side view. ELCRX alternatives are available via the screener, along with tax-loss harvesting opportunities.